|
20 Jun 2019 |
News |
No Difference Among Biologics in Arthroplasty Infectious Risk |
|
|
18 Jun 2019 |
News |
Is Methotrexate Necessary with Tofacitinib? |
|
|
17 Jun 2019 |
Social |
Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars |
|
|
29 May 2019 |
Social |
FDA has approved the worlds most expensive drug - $2.1 million - Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy for spinal muscular atrophy (SMA) that affects 1 in 11,000 newborns https://t.co/hHuymQ3sjV |
|
|
28 May 2019 |
News |
Upadacitinib Monotherapy in MTX-IR Rheumatoid Arthritis |
|
|
28 May 2019 |
News |
Predictors of Serious Infections with Rituximab |
|
|
21 May 2019 |
News |
Nintedanib May Benefit Systemic Sclerosis Related Interstitial Lung Disease |
|
|
20 May 2019 |
News |
EMA Restricts Tofacitinib Dosing |
|
|
15 May 2019 |
News |
FDA Final Guidance on Interchangeability with Biosimilars |
|
|
09 May 2019 |
Social |
Biologic Survival study from Japan- ANSWER study w/ 4466 courses in 2494 pts (2009-17). Efficacy Survival best for ABA, TCZ; worst for IFX & CZP. Toxicity Dropouts most in IFX & ADA, least ABA & CZP. Remission best w/ ETN & ABA, least w/ GLM, IFX. https://t.co/IgRDKLemjW |
|
|
08 May 2019 |
Social |
FDA has approved Ruzurgi (amifampridine) for Lambert-Eaton myasthenic syndrome in children 6-17 years. Drug works by blocking potassium channel efflux in nerve terminals, opening Ca2+ channels & increasing acetylcholine release https://t.co/y7JFr76PTr |
|
|
29 Apr 2019 |
Social |
FDA has approved Samsung-Bioepsis biosimilar version of etanercept - Eticovo (etanercept-ykro), approved in other countries under names Benepali and Brenzys. Approval based on 596 RA pt trial w/ 52 wk ACR20 of 80.8% and 81.5% (Enbrel arm) https://t.co/r3q9dQ0Bdb |
|
|
24 Apr 2019 |
News |
Ustekinumab Effective in Behcet's Disease |
|
|
23 Apr 2019 |
Social |
CORRONA study of 880 RA pts w/ hx of Solid cancer shows many on biologics following Dx. 42% were on biologics/tsDMARDs in the 12 mo before cancer. Post CA 31% were on same Rx, 5% switched biologics &10% started a biologic, the majority starting TNFi (54%). https://t.co/PjjQvFVnsI |
|
|
18 Apr 2019 |
News |
Polypharmacy Blunts Responses and Ups the Safety Risks |
|
|
11 Apr 2019 |
Social |
117 pregnancies exposed to biologics were compared to 585 pregnancies not exposed to biologics; 6% of newborns had ≥1 congenital anomalies. No significant association between biologic exposure and congenital anomalies (HR 1.06; 95%CI 0.46-2.47) was seen. https://t.co/bLOtPTmpL1 |
|
|
04 Apr 2019 |
ACR Video |
A Video Collage of RheumNow Live 2019 |
|
|
01 Apr 2019 |
News |
RheumNowLive On Demand: Development & Use of JAK Inhibitors - Dr. John O'Shea |
|
|
28 Mar 2019 |
News |
For RA With COPD, Abatacept is Safe |
|
|
28 Mar 2019 |
News |
Ups and Downs with Abatacept |
|
